Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Dena DeMarco"'
Autor:
Shang-Yi Huang, Yuan-Bin Yu, Su-Peng Yeh, Tsai-Yun Chen, Woei-Yau Kao, Chih-Cheng Chen, Ming-Chung Wang, Hsuan-Yu Lin, Sheng-Fung Lin, Tseng-Hsi Lin, Ye Hua, Marie Puccio-Pick, Dena DeMarco, Christian Jacques, Po Dunn
Publikováno v:
Journal of the Formosan Medical Association, Vol 116, Iss 9, Pp 705-710 (2017)
The incidence of multiple myeloma in Asia has risen in the past 30 years. Lenalidomide, an IMiD immunomodulatory agent, has improved the overall survival in patients with relapsed/refractory multiple myeloma (RRMM) when used with dexamethasone versus
Externí odkaz:
https://doaj.org/article/18e464b7bd064d5fbd2ab6b72dc4cf2e
Autor:
Tommy Li, Ida H. Hiemstra, Christopher Chiu, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Theodora Salcedo, Frederikke Lihme Egerod, Kate Sasser, Tahamtan Ahmadi, Manish Gupta
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:1108-1119
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion of T cells and killi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5151e781ab00ccc5120d8c6f950d1fa4
https://doi.org/10.1002/cpt.2729
https://doi.org/10.1002/cpt.2729
Autor:
Rogier Mous, Ada Azaryan, Brian Elliott, Tommy Li, Dena DeMarco, Martine E.D. Chamuleau, Kim Linton, David John Lewis, Anna Sureda Balari, Roberto S. Oliveri, Pieternella J. Lugtenburg, Martin Hutchings, Michael Roost Clausen, Kuo mei Chen, Tahamtan Ahmadi, David Cunningham, Peter Johnson, Christopher Chiu
Publikováno v:
The Lancet, 398(10306), 1157-1169. Elsevier Limited
The Lancet, 398(10306), 1157-1169. Elsevier Ltd.
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
The Lancet, 398(10306), 1157-1169. Elsevier Ltd.
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af475f2eb2549d35a7595f199ce1bd0f
https://research.vumc.nl/en/publications/f3dfa4ae-9861-4d28-8f31-26e4b87ec3e5
https://research.vumc.nl/en/publications/f3dfa4ae-9861-4d28-8f31-26e4b87ec3e5
Autor:
Brian Elliott, Martine E.D. Chamuleau, Kuo-mei Chen, Anna Sureda Balari, Martin Hutchings, David John Lewis, Michael Roost Clausen, David Cunningham, Peter Johnson, Dena DeMarco, Rogier Mous, Kim Linton, Pieternella J. Lugtenburg
Publikováno v:
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K, Lewis, D J, Chamuleau, M E D, Balari, A S, Cunningham, D, DeMarco, D, Chen, K-M, Elliott, B & Lugtenburg, P 2021, ' Subcutaneous epcoritamab in patients with relapsed/refractory b-cell non-hodgkin lymphoma: safety profile and anti-tumor activity ', Hematological Oncology, vol. 39, no. Suppl. 2, 016, pp. 42 . https://doi.org/10.1002/hon.16_2879
7518 Background: Epcoritamab is a CD20xCD3 bispecific antibody that induces T-cellmediated killing of CD20–positive malignant B-cells. We present updated data, including progression-free survival (PFS) from the dose escalation part of the first-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7844c97f450a3c75a4c1e28fa87ad5a0
https://doi.org/10.1002/hon.16_2879
https://doi.org/10.1002/hon.16_2879
Autor:
David John Lewis, Rogier Mous, David Cunningham, Peter Johnson, Kuo-mei Chen, Martin Hutchings, Dena DeMarco, Anna Sureda Balari, Brian Elliott, Martine E.D. Chamuleau, Michael Roost Clausen, Kim Linton, Roberto S. Oliveri, Pieternella J. Lugtenburg
Publikováno v:
Annals of Oncology. 32:S292
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33fa2c8bb42af361d1148835a2d4367f
https://doi.org/10.1016/j.annonc.2021.05.546
https://doi.org/10.1016/j.annonc.2021.05.546
Autor:
Frederikke Lihme Egerod, Tommy Li, Theodora W. Salcedo, Manish Gupta, Christopher Chiu, Roberto S. Oliveri, Ida H. Hiemstra, Dena DeMarco
Publikováno v:
Blood. 136:35-36
Introduction: Epcoritamab (DuoBody-CD3×CD20) is a subcutaneously administered bispecific antibody (bsAb) that simultaneously binds to CD3 on T cells and CD20 on malignant B cells, resulting in T-cell activation and expansion and selective T-cell-med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f17673b2dffec8b2e7a5e5bec72939f7
https://doi.org/10.1182/blood-2020-139457
https://doi.org/10.1182/blood-2020-139457
Autor:
Brian Elliott, Martine E.D. Chamuleau, Rogier Mous, Kim Linton, Anna Sureda Balari, Kuo-mei Chen, Martin Hutchings, Michael Roost Clausen, David Cunningham, Peter Johnson, Roberto S. Oliveri, Pieternella J. Lugtenburg, Dena DeMarco, David John Lewis
Publikováno v:
Hutchings, M, Mous, R, Roost Clausen, M, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Balari, A S, Cunningham, D, Oliveri, R S, DeMarco, D, Elliott, B, Chen, K & J. Lugtenburg, P 2020, ' Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy : Updated Dose Escalation Data ', Blood, bind 136, nr. Suppl. 1, s. 45-46 . https://doi.org/10.1182/blood-2020-133820
Introduction: Despite advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL), more efficacious, less toxic, off-the-shelf therapies are needed for patients (pts) with relapsed or refractory (R/R) disease. Epcoritamab is a novel, subcutaneou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c71fc8d31d3b19fc813ef0321af94bb
https://doi.org/10.1182/blood-2020-133820
https://doi.org/10.1182/blood-2020-133820
Autor:
Peter Johnson, Juanita Lopez, Brian Elliott, Martin Hutchings, Martine E.D. Chamuleau, Kim Linton, Dena DeMarco, Roberto S. Oliveri, Simon Rule, Pieternella J. Lugtenburg, Rogier Mous, Michael Roost Clausen
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S274
Context: CD3×CD20 bispecific antibodies (bsAbs) have demonstrated promising results in R/R B-NHL. Epcoritamab is a novel subcutaneously-administered bsAb with a favorable safety profile and encouraging preliminary anti-tumor activity in both aggress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24d4412bb2ef11b70133f7a273474da5
https://doi.org/10.1016/s2152-2650(20)30891-0
https://doi.org/10.1016/s2152-2650(20)30891-0
Autor:
Michael Roost Clausen, Brian Elliott, Martine E.D. Chamuleau, Rogier Mous, Kim Linton, Simon Rule, Roberto S. Oliveri, Pieternella J. Lugtenburg, Dena DeMarco, Martin Hutchings, Peter Johnson, Juanita Lopez
Publikováno v:
Web of Science
Hutchings, M, Lugtenburg, P, Mous, R, Clausen, M R, Chamuleau, M, Linton, K, Rule, S, Lopez, J S, Oliveri, R S, DeMarco, D, Elliott, B & Johnson, P 2020, ' Epcoritamab (GEN3013; DuoBody-CD3xCD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial ', Journal of Clinical Oncology, vol. 38, no. Suppl. 15, 8009 . https://doi.org/10.1200/JCO.2020.38.15_suppl.8009?af=R
Hutchings, M, Lugtenburg, P, Mous, R, Clausen, M R, Chamuleau, M, Linton, K, Rule, S, Lopez, J S, Oliveri, R S, DeMarco, D, Elliott, B & Johnson, P 2020, ' Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) : Complete dose escalation data and efficacy results from a phase I/II trial. ', Journal of Clinical Oncology, vol. 38, no. Suppl. 15, 8009 . https://doi.org/10.1200/JCO.2020.38.15_suppl.8009
Hutchings, M, Lugtenburg, P, Mous, R, Clausen, M R, Chamuleau, M, Linton, K, Rule, S, Lopez, J S, Oliveri, R S, DeMarco, D, Elliott, B & Johnson, P 2020, ' Epcoritamab (GEN3013; DuoBody-CD3xCD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial ', Journal of Clinical Oncology, vol. 38, no. Suppl. 15, 8009 . https://doi.org/10.1200/JCO.2020.38.15_suppl.8009?af=R
Hutchings, M, Lugtenburg, P, Mous, R, Clausen, M R, Chamuleau, M, Linton, K, Rule, S, Lopez, J S, Oliveri, R S, DeMarco, D, Elliott, B & Johnson, P 2020, ' Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) : Complete dose escalation data and efficacy results from a phase I/II trial. ', Journal of Clinical Oncology, vol. 38, no. Suppl. 15, 8009 . https://doi.org/10.1200/JCO.2020.38.15_suppl.8009
8009 Background: CD3×CD20 bispecific antibodies (bsAbs) have demonstrated promising results for the treatment of pts with R/R B-NHL. Epcoritamab is a novel subcutaneously administered bsAb with a favorable safety profile and encouraging preliminary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bae7c07ffd752b0b8ae16a65c9e3209
https://doi.org/10.1200/jco.2020.38.15_suppl.8009
https://doi.org/10.1200/jco.2020.38.15_suppl.8009
Autor:
Rogier Mous, Tahamtan Ahmadi, Guang Chen, Peter Johnson, Martin Hutchings, Dena DeMarco, Martine E.D. Chamuleau, Kim Linton, Manish Gupta, Michael Roost Clausen, Simon Rule, Roberto S. Oliveri, Ada Azaryan, Ida H. Hiemstra, Pieternella J. Lugtenburg
Publikováno v:
Blood. 134:758-758
Introduction: CD20-specific monoclonal antibodies (mAbs) have demonstrated efficacy in the treatment of B-cell non-Hodgkin lymphomas (B-NHL); however, a significant proportion of patients (pts) present with refractory disease or will experience relap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10ad53efdbc98eb603c3636c555aa1e7
https://doi.org/10.1182/blood-2019-121460
https://doi.org/10.1182/blood-2019-121460